Loading…
Reported covered position: Staff Dir., Subcomm., House Committee on Homeland Security
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Inflation Reduction Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Accelerated Approval Integrity Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2022 · third_quarter · Q3
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
H.R.6963 - Accelerated Approval Integrity Act of 2022; All Provisions
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Protecting Health Care for All Patients Act of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Food and Drug Amendments of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
Food and Drug Amendments of 2022
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
American Data Privacy and Protection Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
H.R.5376 - Inflation Reduction Act of 2022; Healthcare provisions of the bill H.R.7634 - Protecting Health Care for All Patients Act of 2022; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill S.350 - Newborn Screening Saves Lives Reauthorization Act of 2021; All provisions of the bill S.4348 - FDASLA Act of 2022; All provisions of the bill Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023; healthcare provisions of the bill Issues related to rare disease Issues related to patient access treatments Issues related to newborn screening Issues related to Prescription Drug User Fee Program Reauthorization
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.2158 - Newborn Screening Saves Lives Reauthorization Act of 2019
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Prescription Drug Pricing Reduction Act of 2019
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
Making further continuing appropriations for fiscal year 2018, and for other purposes.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
An Act to amend the Homeland Security Act of 2002 to require the Secretary of Homeland Security to issue Department of Homeland Security-wide guidance and develop training programs as part of the Department of Homeland Security Blue Campaign, and for other purposes.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Consolidated Appropriations Act, 2018
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
American Health Care Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Bipartisan Budget Act of 2018
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
FDA Reauthorization Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Consolidated Appropriations Act, 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Medicaid Drug Rebate Program, coverage, state level implementation, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Lower Drug Costs through Competition Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Providing for consideration of the concurrent resolution (H. Con. Res. 71) establishing the congressional budget for the United States Government for fiscal year 2018 and setting forth the appropriate budgetary levels for fiscal years 2019 through 2027.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Medicaid Drug Rebate Program, coverage, state level implementation, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Affordable and Safe Prescription Drug Importation Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
Improving Access To Affordable Prescription Drugs Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2018 and setting forth the appropriate budgetary levels for fiscal years 2019 through 2027.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Making further continuing appropriations for fiscal year 2018, and for other purposes.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
An Act to amend the Homeland Security Act of 2002 to require the Secretary of Homeland Security to issue Department of Homeland Security-wide guidance and develop training programs as part of the Department of Homeland Security Blue Campaign, and for other purposes.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
American Health Care Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
American Health Care Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
American Health Care Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
FDA Reauthorization Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
FDA Reauthorization Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
FDA Reauthorization Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
Consolidated Appropriations Act, 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res.3 - Senate Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
Consolidated Appropriations Act, 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
Consolidated Appropriations Act, 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Medicaid Drug Rebate Program, coverage, state level implementation H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Medicaid Drug Rebate Program, coverage, state level implementation, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Lower Drug Costs through Competition Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
Lower Drug Costs through Competition Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
Lower Drug Costs through Competition Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
Providing for consideration of the concurrent resolution (H. Con. Res. 71) establishing the congressional budget for the United States Government for fiscal year 2018 and setting forth the appropriate budgetary levels for fiscal years 2019 through 2027.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Providing for consideration of the concurrent resolution (H. Con. Res. 71) establishing the congressional budget for the United States Government for fiscal year 2018 and setting forth the appropriate budgetary levels for fiscal years 2019 through 2027.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
Medicaid Drug Rebate Program, coverage, state level implementation H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Medicaid Drug Rebate Program, coverage, state level implementation, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 Various bills on transparency and affordability of prescription drugs
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
Affordable and Safe Prescription Drug Importation Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
Improving Access To Affordable Prescription Drugs Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
Improving Access To Affordable Prescription Drugs Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
Improving Access To Affordable Prescription Drugs Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2018 and setting forth the appropriate budgetary levels for fiscal years 2019 through 2027.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2018 and setting forth the appropriate budgetary levels for fiscal years 2019 through 2027.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res.3 - Senate Budget Resolution appropriations generally, no specific bill
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
S.Con.Res.3 - Senate Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations H.R. 2028 - Further Continuing and Security Assitance Appropriations Act, 2017
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Bipartisan Budget Act of 2015
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations H.R. 2028 - Further Continuing and Security Assitance Appropriations Act, 2017
Bipartisan Budget Act of 2015
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations
Bipartisan Budget Act of 2015
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Bipartisan Budget Act of 2015
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Further Continuing and Security Assistance Appropriations Act, 2017
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations H.R. 2028 - Further Continuing and Security Assitance Appropriations Act, 2017
Consolidated Appropriations Act, 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Consolidated Appropriations Act, 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations H.R. 2028 - Further Continuing and Security Assitance Appropriations Act, 2017
Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response. H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Patient-Focused Impact Assessment Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Patient-Focused Impact Assessment Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response. H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Patient-Focused Impact Assessment Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Patient-Focused Impact Assessment Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Advancing Hope Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response. H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Advancing Hope Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Advancing Hope Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Advancing Hope Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: SAREPTA THERAPEUTICS, INC. · Firm: SAREPTA THERAPEUTICS, INC.
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
2022 · second_quarter · Q2
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2022 · first_quarter · Q1
H.R.6963 - Accelerated Approval Integrity Act of 2022; All Provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2021 · third_quarter · Q3
Introduction to company, matters affecting regulatory policy and innovation
Filing targets: SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2021 · second_quarter · Q2
Medicaid Coverage and Access, Center for Biologics Evaluation and Research Funding, Gene Therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2021 · first_quarter · Q1
Supply Chain and Medicaid Access
Filing targets: Centers For Disease Control & Prevention (CDC), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2020 · fourth_quarter · Q4
Matters regarding FDA topics and gene therapy
Filing targets: SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2020 · second_quarter · Q2
CURES 2.0; Health Care Coverage Modernization; Regulatory Modernization
Filing targets: HOUSE OF REPRESENTATIVES
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2020 · first_quarter · Q1
S.2158 - Newborn Screening Saves Lives Reauthorization Act of 2019
Filing targets: SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · fourth_quarter · Q4
H.R. 2507 - Newborn Screening Saves Lives Reauthorization Act of 2019 S.2543 - Prescription Drug Pricing Reduction Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · third_quarter · 3A
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · third_quarter · Q3
H.R.2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements for gene therapy and value-based payments (No specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · second_quarter · 2A
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · first_quarter · 1A
Newborn Screening Saves Lives Reauthorization Act; Value and Efficiency Act; Patient Affordability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · second_quarter · Q2
H.R.2507 Newborn Screening Saves Lives Reauthorization Act of 2019 Discussions regarding State Medicaid access, innovative payment arrangements and value-based payments (No specific bill)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2019 · first_quarter · Q1
Newborn Screening Saves Lives Reauthorization Act; Value and Efficiency Act; Patient Affordability
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2018 · fourth_quarter · Q4
Communication regarding education and outreach of company; Communication regarding Newborn Screening Saves Lives Reauthorization Act; Communication regarding Medicaid access and approval
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2018 · first_quarter · Q1
Medicaid Drug Rebate Program, coverage, state level implementation, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 S. 456 - RACE for Children Act HR 1625 - Consolidated Appropriations Act of 2018 HR 1892 - Bipartisan Budget Act of 2018
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2017 · fourth_quarter · Q4
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017
Medicaid Drug Rebate Program, coverage, state level implementation, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2017 · third_quarter · Q3
Medicaid Drug Rebate Program, coverage, state level implementation H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017 Graham-Cassidy Amendment
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2017 · second_quarter · Q2
S.Con.Res.3 - Senate Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 appropriations generally, no specific bill
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 S.771 - Improving Access To Affordable Prescription Drugs Act S.637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 S.469 - Affordable and Safe Prescription Drug Importation Act HR 749 - Lower Drug Costs Through Competition Act HR 1628 - American Health Care Act HR 2430 - FDA Reauthorization Act of 2017 Better Care Reconciliation Act of 2017
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2017 · first_quarter · Q1
Issues: Innovation, Duchenne muscular dystrophy, platform technologies PL 114-255 - 21st Century Cures implementation S.204 - Right to Try Act of 2017 Various bills on transparency and affordability of prescription drugs
Medicaid Drug Rebate Program, coverage, state level implementation
S.Con.Res.3 - Senate Budget Resolution appropriations generally, no specific bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2016 · fourth_quarter · Q4
Medicaid Drug Rebate Program and coverage
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations H.R. 2028 - Further Continuing and Security Assitance Appropriations Act, 2017
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2016 · third_quarter · Q3
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act S. 2912 - Right to Try Act
Medicaid Drug Rebate Program and coverage
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 5325 - Continuing Appropriations
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2016 · second_quarter · Q2
Medicaid Program and Pharmaceuticals
Pharmaceutical innovation, precision medicine, rare diseases, platform technologies, Innovation For Healthier Americans H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2016 · first_quarter · Q1
Medicaid Program and Pharmaceuticals
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response. H.R. 6 - 21st Century Cures S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 2700 - FDA and NIH Workforce Authorities Modernization Act S. 2713 - Advancing Precision Medicine Act of 2016 S. 2742 - Promoting Biomedical Research and Public Health for Patients Act S. 1878 - Advancing Hope Act S. 1597 - Patient Focused Impact Assessment Act
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2015 · fourth_quarter · Q4
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response. H.R. 6 - 21st Century Cures Act Senate "Innovation For Healthier Americans" initiative S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015
H.R. 9 - Innovation Act S. 779 - Fair Access to Science and Technology Research Act of 2015 S. 1137 - PATENT Act
Medicaid Program and Pharmaceuticals
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2015 · third_quarter · Q3
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 83 - Consolidated and Future Continuing Appropriations Act, 2015
H.R. 9 - Innovation Act S. 779 - Fair Access to Science and Technology Research Act of 2015 S. 1137 - PATENT Act
Medicaid Program and Pharmaceuticals
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2015 · second_quarter · Q2
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response; 21st Century Cures Initiative. H.R. 6 - 21st Century Cures Act
H.R. 9 - Innovation Act S. 779 - Fair Access to Science and Technology Research Act of 2015 S. 1137 - PATENT Act
H.R. 83 - Consolidated and Future Continuing Appropriations Act of 2015 H. Con. Res. 27 - House Budget Resolution S. Con. Res. 11 - Senate Budget Resolution Public health and emerging infectious disease preparedness and response.
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2015 · first_quarter · Q1
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response; 21st Century Cures Initiative.
H. Con. Res. 27 -- Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025; S. Con. Res. 11 -- An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025; public health and emerging infectious disease preparedness and response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2014 · fourth_quarter · 4A
Consolidated and Further Continuing Appropriations Act of 2015 (H.R. 83); Public health and emerging infectious disease preparedness and response.
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response; 21st Century Cures Initiative.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2014 · fourth_quarter · Q4
Consolidated and Further Continuing Appropriations Act of 2015 (H.R. 83); Public health and emerging infectious disease preparedness and response.
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response; 21st Century Cures Initiative.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAREPTA THERAPEUTICS, INC. via SAREPTA THERAPEUTICS, INC.
2014 · fourth_quarter · RR
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response.
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response.
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
S.Con.Res. 25 - Senate Budget Resolution H.Res. 553 - House Budget Resolution HR 244 - Consolidated Appropriations Act of 2017 H.J.Res. 123, HR 1370 - Continuing Resolution appropriations generally, no specific bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Medicaid Drug Rebate Program, coverage, state level implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H. Con. Res. 27 - House budget resolution S. Con. Res. 11 - Senate budget resolution H.R. 1314 - Bipartisan Budget Act of 2015 H.R. 2029 - Consolidated Appropriations Act, 2016
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Pharmaceutical interventions for orphan and infectious disease indications; public health, emerging infectious disease preparedness and response. H.R. 6 - 21st Century Cures Act Senate "Innovation For Healthier Americans" initiative S. 2030 - Advancing Targeted Therapies for Rare Diseases Act of 2015
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE